chartexchange

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 13, 2026 4:47 PM EST

Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903

Read original article